Genmab - Castor præsentation på ASCO 2016
-
Offentliggjort den 5. jun. 2016
Antonio Palumbo, Asher Alban Akmal Chanan-Khan, Katja Weisel, et alt. Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. Abstract LBA4.
-
Genmab - Offentliggjort den 5. jun. 2016
Dr. Sagar Lonial from the Winship Cancer Institute, talks about the multiple myeloma clinical trials and abstracts presented at the annual American Society of Clinical Oncologists (ASCO) meeting in Chicago, IL.
-
Genmab - Mere fra Antonio Palumbo.
Offentliggjort den 5. jun. 2016
Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the phase III results of the CASTOR trial, which was a randomized controlled study examining the efficacy of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
-
Genmabs vidundermiddel leverer historisk gode data.
-
Fra Plenary Session:
Start 2,38.
-
-
Castorvideo.
Offentliggjort den 6. jun. 2016
Antonio Palumbo, MD, discusses the "unprecedented" results of the CASTOR Trial, a plenary, late-breaking abstract at ASCO 2016.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind